Sensei Biotherapeutics to Present SNS-103 Preclinical Data at CRI-ENCI Immunotherapy Conference
BOSTON, Sept. 04, 2024 -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a company at the forefront of immuno-oncology, has announced that it will present preclinical data on SNS-103 at an upcoming conference. The data will be showcased at a poster session during the CRI-ENCI Eighth International Immunotherapy Conference, scheduled from September 8 to 11, 2024, at the Gaylord National Resort & Convention Center in National Harbor, MD.
Presentation Details:
CRI-ENCI Eighth International Cancer Immunotherapy Conference
Title: Pre-clinical characterization of monoclonal antibodies targeting CD39 activity in the acidic tumor microenvironment
Presenter: F. Donelson Smith, Ph.D., Senior Director, Biologics Discovery & Early Development
Poster Number: 195A
Date and Time: Sunday, September 8, 2024, from 12:05 to 2:05 p.m. EDT
About Sensei Biotherapeutics
Sensei Biotherapeutics (Nasdaq: SNSE) is a clinical-stage company specializing in immuno-oncology, focusing on the discovery and development of innovative cancer treatments. Utilizing its proprietary TMAb™ (Tumor Microenvironment Activated biologics) platform, Sensei creates conditionally active therapeutics. These therapies are designed to either inhibit immunosuppressive signals or stimulate immunostimulatory signals selectively within the tumor microenvironment.
The company’s leading investigational candidate is SNS-101. This conditionally active antibody specifically targets the VISTA (V-domain Ig suppressor of T cell activation) checkpoint within the tumor’s low pH environment. VISTA functions to suppress T cells by binding to the receptor PSGL-1, and SNS-101 aims to block this action.
Additionally, Sensei is advancing several other promising candidates. SNS-102 is a conditionally active monoclonal antibody that targets VSIG-4 (V-Set and Immunoglobulin Domain Containing 4). SNS-103 is another conditionally active monoclonal antibody that focuses on ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), also known as CD39. Lastly, SNS-201 is a bispecific antibody combining a CD28 agonist arm with a pH-sensitive anti-VISTA arm.
The company's innovative approach aims to provide more effective treatment options for cancer patients by targeting the specific conditions within the tumor microenvironment. Sensei’s research and development efforts are geared towards unlocking new avenues for cancer immunotherapy, offering hope for better patient outcomes.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
